The evaluation of safety and efficacy of colistin use in pediatric intensive care unit: Results from two reference hospitals and review of literature

Basit Öğe Kaydı
dc.contributor.authorBal, Zumrut Sahbudak
dc.contributor.authorCan, Fulya Kamit
dc.contributor.authorYazici, Pinar
dc.contributor.authorAnil, Ayse Berna
dc.contributor.authorDuyu, Muhterem
dc.contributor.authorCiftdogan, Dilek Yilmaz
dc.contributor.authorYilmaz, Ozkalay Nisel
dc.contributor.authorCilli, Feriha
dc.contributor.authorKarapinar, Bulent
dc.date.accessioned2019-10-27T10:06:24Z
dc.date.available2019-10-27T10:06:24Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractColistin, an old cationic polypeptide antibiotic, have been reused due to rising incidence of infections caused by multi-drug resistant (MDR) Gram-negative microorganisms and the lack of new antibiotics. Therefore, we evaluated safety and efficacy of colistin in treatment of these infections. This study included 104 critically ill children with a median age of 55,9 months between January 2011 and January 2016. Nephrotoxicity occurred in 11 (10.5%) patients. Nephrotoxicity occurred between the third and seventh day of treatment in 63% of colistin induced nephrotoxicity episodes. The subgroup analysis between the patients who developed nephrotoxicity during colistin treatment and those that did not, showed no significant difference in terms of age, underlying disease, cause for PICU admission and type of infection required colistin treatment, P values were 0.615, 0.762, 0.621, 0.803, respectively. All patients were receiving a concomitant nephrotoxic agent (P = 0,355). The majority of the patients (52%) were having primary or secondary immune deficiency in treatment failure group and the most common cause of PICU admission was sepsis in treatment failure group, P values were 0.007 and 0.045, respectively. Mortality attributed to colistin failure and crude mortality were 14.4% and 29.8%, respectively. In conclusion, colistin may have a role in the treatment of infections caused by multidrug-resistant Gram-negative bacteria in critically ill children. However, the patients have to be followed for side effects throughout colistin treatment, not for only early stage. And the clinicians should be aware of increase in the rate of nephrotoxicity in patients those have been receiving a concomitant nephrotoxic agent. (C) 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.jiac.2017.12.017en_US
dc.identifier.endpage375en_US
dc.identifier.issn1341-321X
dc.identifier.issn1437-7780
dc.identifier.issue5en_US
dc.identifier.pmid29361414en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage370en_US
dc.identifier.urihttps://doi.org/10.1016/j.jiac.2017.12.017
dc.identifier.urihttps://hdl.handle.net/11454/30451
dc.identifier.volume24en_US
dc.identifier.wosWOS:000429337700009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofJournal of Infection and Chemotherapyen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColistinen_US
dc.subjectCarbapenem-resistant gram-negative bacteriaen_US
dc.subjectChilden_US
dc.subjectCritical careen_US
dc.titleThe evaluation of safety and efficacy of colistin use in pediatric intensive care unit: Results from two reference hospitals and review of literatureen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu